IHL.AX Incannex Healthcare (ASX) A$0.041 -10.87% intraday 10 Mar 2026: watch volume

IHL.AX stock opened the ASX session at A$0.047 and is trading at A$0.041, down 10.87% intraday on 10 Mar 2026. Volume is large at 61,360,016 shares, nearly ten times the average, making Incannex Healthcare Limited (IHL.AX) one of today’s most active ASX names. Traders are reacting to thin capitalization, recent clinical updates, and low liquidity that amplify moves in this healthcare small cap.

Intraday snapshot: IHL.AX stock movement

Incannex Healthcare Limited (IHL.AX) trades on the ASX at A$0.041 with a day low of A$0.041 and a day high of A$0.051. The previous close was A$0.046, so the stock is down -10.87% for the session on heavy turnover.

Volume of 61,360,016 compares with an average volume of 6,427,691, giving a relative volume of 9.55 and confirming the ‘most active’ designation for intraday screens.

Drivers today: clinical news, liquidity and market flow

Price action reflects low market cap and news sensitivity rather than a single headline. Incannex (IHL.AX) is a drug developer with multiple early-stage programs; small updates or ADR coverage spikes can trigger large intraday moves.

The ASX small-cap healthcare sector is softer today, which likely intensified selling. IHL.AX’s market cap is A$14,255,927, so institutional buying or selling can move the share price materially.

Financials and valuation: what the numbers show

IHL.AX shows negative earnings with EPS -1.30 and a trailing P/E of -0.03, reflecting loss-making operations. Book value per share is A$0.0547 and cash per share is A$0.0217, leaving a current ratio of 9.02, which signals short-term liquidity but limited revenue generation.

Key valuation ratios: price to book is 0.75, price to sales is 14.06, and enterprise value is negative at A$-18,320,558, indicating more cash than debt on the balance sheet and a need to monitor dilution risk from financing rounds.

Technicals, liquidity and trading metrics

Short-term technicals show IHL.AX is trading below its 50-day average of A$0.0649 and 200-day average of A$0.10285, marking a multi-month downtrend. Year high is A$0.28 and year low is A$0.041, so today touches the 52-week low.

High turnover with low free float can increase intraday volatility. Average volume is 6,427,691; today’s spike to 61,360,016 may reflect retail flows or ADR-linked activity, not steady institutional accumulation.

Meyka AI rates IHL.AX with a score out of 100

Meyka AI rates IHL.AX with a score out of 100: 65.07 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights strong liquidity metrics but weak earnings and high R&D intensity.

This rating is informational. Meyka AI is an AI-powered market analysis platform; grades are not investment advice and past performance is not indicative of future results.

Risks and catalysts for IHL.AX stock

Primary risks include continued cash burn, trial setbacks across cannabinoid and psychedelic programs, and dilution from capital raises. Regulatory outcomes and Phase II results are binary catalysts for valuation repricing.

Potential upside catalysts are positive clinical readouts, licensing deals, or stronger ADR interest. Given IHL.AX’s market cap and float, any material corporate news could trigger sharp intraday moves.

Final Thoughts

IHL.AX stock is an active intraday mover on 10 Mar 2026, trading at A$0.041 with volume of 61,360,016, and a session decline of -10.87%. The company remains loss-making with EPS -1.30 and thin market capitalisation of A$14.26M, which explains the outsized volatility. Meyka AI’s forecast model projects a 12-month guideline target of A$0.090, implying an upside of +119.51% versus the current price of A$0.041. Forecasts are model-based projections and not guarantees. For traders, today’s activity signals high short-term risk and opportunity due to liquidity and news sensitivity. For longer-term investors, key checks are trial milestones, cash runway, and dilution risk before considering a position. See the live IHL.AX page on Meyka for updates and the latest intraday feed Meyka IHL.AX page. For market news reference see Investing.com coverage of Incannex ADR.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.